Autores
Eric Van Cutsem, Andrés Cervantes, Rene Adam, Alberto Sobrero, JH Van Krieken, D Aderka, E Aranda Aguilar, Alberto Bardelli, A Benson, G Bodoky, F Ciardiello, André D'Hoore, Eduardo Diaz-Rubio, J-Y Douillard, M Ducreux, Alfredo Falcone, A Grothey, T Gruenberger, Karin Haustermans, Volker Heinemann, P Hoff, C-H Köhne, R Labianca, Pierre Laurent-Puig, B Ma, Tim Maughan, K Muro, Nicola Normanno, P Österlund, WJG Oyen, D Papamichael, G Pentheroudakis, P Pfeiffer, TJ Price, C Punt, J Ricke, A Roth, R Salazar, W Scheithauer, HJ Schmoll, J Tabernero, J Taïeb, Sabine Tejpar, H Wasan, T Yoshino, A Zaanan, D Arnold
Fecha de publicación
2016/8/1
Revista
Annals of Oncology
Volumen
27
Número
8
Páginas
1386-1422
Editor
Elsevier
Descripción
Colorectal cancer (CRC) is one of the most common malignancies in Western countries. Over the last 20 years, and the last decade in particular, the clinical outcome for patients with metastatic CRC (mCRC) has improved greatly due not only to an increase in the number of patients being referred for and undergoing surgical resection of their localised metastatic disease but also to a more strategic approach to the delivery of systemic therapy and an expansion in the use of ablative techniques. This reflects the increase in the number of patients that are being managed within a multidisciplinary team environment and specialist cancer centres, and the emergence over the same time period not only of improved imaging techniques but also prognostic and predictive molecular markers. Treatment decisions for patients with mCRC must be evidence-based. Thus, these ESMO consensus guidelines have been developed …
Artículos de Google Académico
E Van Cutsem, A Cervantes, R Adam, A Sobrero… - Annals of Oncology, 2016